MorphoSys (ETR:MOR) Reaches New 12-Month High at $68.00

MorphoSys AG (ETR:MOR) reached a new 52-week high during trading on Wednesday . The stock traded as high as €68.00 ($72.34) and last traded at €67.70 ($72.02), with a volume of 122121 shares trading hands. The stock had previously closed at €67.70 ($72.02).

MorphoSys Price Performance

The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of -12.24, a P/E/G ratio of 0.06 and a beta of 0.61. The business has a 50 day simple moving average of €66.05 and a 200-day simple moving average of €42.68. The company has a debt-to-equity ratio of 526.17, a quick ratio of 3.49 and a current ratio of 3.08.

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.